These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38831868)

  • 1. Effectiveness of the Use of the Human Recombinant Epidermal Growth Factor in the Subsidized Regime vs The Contributive Regime in Patients with Venous Ulcers in Bogotá.
    Cacua Sanchez MT; Buenahora G; Carrillo Bravo CA
    Drug Des Devel Ther; 2024; 18():1933-1945. PubMed ID: 38831868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socio-Demographic Characteristics and Associated Factors of Morbidity in Patients with Venous Ulcers Treated in Two Institutions of Contributive and Subsidized Regime in Colombia: Retrospective, Multicenter, Observational Study.
    Cacua Sanchez MT; Buenahora G
    Vasc Health Risk Manag; 2022; 18():89-104. PubMed ID: 35264854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Human Recombinant Epidermal Growth Factors vs Conventional Therapy for the Treatment of Chronic Venous Ulcers: A Retrospective Case Series.
    Cacua Sanchez MT; Giraldo LF; Díaz JA
    Wounds; 2021 Feb; 33(2):41-49. PubMed ID: 33591927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of intralesional and perilesional recombinant human epidermal growth factor vs hydrocolloid therapy in venous ulcer treatment in the Colombian context.
    Cacua Sánchez MT; Botero AM; Moreno-Mattar O
    J Vasc Surg Venous Lymphat Disord; 2024 Mar; 12(2):101745. PubMed ID: 38145819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial.
    Gomez-Villa R; Aguilar-Rebolledo F; Lozano-Platonoff A; Teran-Soto JM; Fabian-Victoriano MR; Kresch-Tronik NS; Garrido-Espíndola X; Garcia-Solis A; Bondani-Guasti A; Bierzwinsky-Sneider G; Contreras-Ruiz J
    Wound Repair Regen; 2014; 22(4):497-503. PubMed ID: 25041620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Intralesional and Perilesional Human Recombinant Epidermal Growth Factor (hrEGF) in the Local Treatment of Venous Ulcer - Review Article - Expert Recommendation.
    Cacua Sanchez MT; Vargas Abello LM; Orrego Á; Ortiz P; Segura H; Berrio Caicedo JJ; Zuluaga LM; Ordoñez J; Fernández Montequin JI; Ulloa J
    Vasc Health Risk Manag; 2023; 19():595-603. PubMed ID: 37701155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers.
    Falanga V; Eaglstein WH; Bucalo B; Katz MH; Harris B; Carson P
    J Dermatol Surg Oncol; 1992 Jul; 18(7):604-6. PubMed ID: 1624634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VenUS IV (Venous leg Ulcer Study IV) - compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-treatment comparison and decision-analytic model.
    Ashby RL; Gabe R; Ali S; Saramago P; Chuang LH; Adderley U; Bland JM; Cullum NA; Dumville JC; Iglesias CP; Kang'ombe AR; Soares MO; Stubbs NC; Torgerson DJ
    Health Technol Assess; 2014 Sep; 18(57):1-293, v-vi. PubMed ID: 25242076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers.
    Romero Prada M; Roa C; Alfonso P; Acero G; Huérfano L; Vivas-Consuelo D
    Diabet Foot Ankle; 2018; 9(1):1480249. PubMed ID: 29963295
    [No Abstract]   [Full Text] [Related]  

  • 10. Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial.
    Park KH; Han SH; Hong JP; Han SK; Lee DH; Kim BS; Ahn JH; Lee JW
    Diabetes Res Clin Pract; 2018 Aug; 142():335-344. PubMed ID: 29902542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human recombinant epidermal growth factor in skin lesions: 77 cases in EPItelizando project.
    Esquirol-Caussa J; Herrero-Vila E
    J Dermatolog Treat; 2019 Feb; 30(1):96-101. PubMed ID: 29683361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Recombinant Human Epidermal Growth Factor for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Clinical Trials.
    Yang Q; Zhang Y; Yin H; Lu Y
    Ann Vasc Surg; 2020 Jan; 62():442-451. PubMed ID: 31394225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers.
    Jaschke E; Zabernigg A; Gattringer C
    Int J Dermatol; 1999 May; 38(5):380-6. PubMed ID: 10369552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The social and economic burden of venous leg ulcers: focus on the role of micronized purified flavonoid fraction adjuvant therapy.
    Simka M; Majewski E
    Am J Clin Dermatol; 2003; 4(8):573-81. PubMed ID: 12862500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral aspirin for treating venous leg ulcers.
    de Oliveira Carvalho PE; Magolbo NG; De Aquino RF; Weller CD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009432. PubMed ID: 26889740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcer due to chronic venous disease: a sociodemographic study in northeastern Brazil.
    de Souza EM; Yoshida WB; de Melo VA; Aragão JA; de Oliveira LA
    Ann Vasc Surg; 2013 Jul; 27(5):571-6. PubMed ID: 23540674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dressings and topical agents for treating venous leg ulcers.
    Norman G; Westby MJ; Rithalia AD; Stubbs N; Soares MO; Dumville JC
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012583. PubMed ID: 29906322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservative versus surgical treatment of venous leg ulcers: a prospective, randomized, multicenter trial.
    van Gent WB; Hop WC; van Praag MC; Mackaay AJ; de Boer EM; Wittens CH
    J Vasc Surg; 2006 Sep; 44(3):563-71. PubMed ID: 16950434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of venous leg ulcer healing and recurrence after treatment with endovenous laser ablation.
    Marston WA; Crowner J; Kouri A; Kalbaugh CA
    J Vasc Surg Venous Lymphat Disord; 2017 Jul; 5(4):525-532. PubMed ID: 28623990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the therapeutic efficacy of magneto-LED therapy and magnetostimulation applied as the adjuvant treatment of venous leg ulcers - preliminary study.
    Pasek J; Szajkowski S; Cieślar G
    Electromagn Biol Med; 2024 Apr; 43(1-2):95-106. PubMed ID: 38449355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.